Tender notice
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Notice details
- Published
- Category
- goods
- Buyer region
- North West
- Source
- View official notice
Public buyer
Public buyer
NHS EnglandTender value£2,028,332,000
- Planned startAs published in the notice
- Planned endAs published in the notice
Work description
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Offer reference number: CM/PHR/24/5680
CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027
CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome.
Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at:
Phone: 0800 9956035
E-mail: support-health@atamis.co.uk